Therapeutically relevant plasma concentrations of memantine produce significant L-N-methyl-D-aspartate receptor occupation and do not impair learning in rats

Behavioural Pharmacology

Volumn 19, Issue 7, 2008, Pages 724-734

  Morè, Lorenzo ^a   Gravius, Andreas ^a   Nagel, Jens ^a   Valastro, Barbara ^a   Greco, Sergio ^a   Danysz, Wojciech ^a,b  

^a Merz Pharmaceuticals GmbH   (Germany)

^b MERZ PHARMACEUTICALS GMBH   (Germany)

Author keywords

Memantine; Microdialysis; Passive avoidance; Rat; Receptor occupancy; Subchronic administration; Working memory

Indexed keywords

MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

ANIMAL EXPERIMENT; ARTICLE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; HYPERACTIVITY; LEARNING DISORDER; MALE; MAZE TEST; MICRODIALYSIS; NEUROPROTECTION; NONHUMAN; OSMOTIC PUMP; PASSIVE AVOIDANCE; PATCH CLAMP; RAT; RECEPTOR BINDING; RECEPTOR OCCUPANCY; TASK PERFORMANCE; WORKING MEMORY;

ANIMALS; AVOIDANCE LEARNING; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEAR; FEMALE; MALE; MAZE LEARNING; MEMANTINE; MEMORY, SHORT-TERM; MICRODIALYSIS; MOTOR ACTIVITY; NEURONAL PLASTICITY; NEUROPROTECTIVE AGENTS; RATS; RATS, SPRAGUE-DAWLEY; REACTION TIME; RECEPTORS, N-METHYL-D-ASPARTATE; RETENTION (PSYCHOLOGY); SEX FACTORS;

EID: 55249115372     PISSN: 09558810     EISSN: None     Source Type: Journal    
DOI: 10.1097/FBP.0b013e3283123cad     Document Type: Article

References (53)

1. Beal MF (2000). Energetics in the pathogenesis of neurodegenerative diseases. Trends Neurosci 23:298-304.
2. Bullock MR, Merchant RE, Carmack CA, Doppenberg E, Shah AK, Wilner KD, et al. (1999). An open-label study of CP-101,606 in subjects with a severe traumatic head injury or spontaneous intracerebral hemorrhage. Ann N Y Acad Sci 890:51-58.
3. Coan EJ, Collingridge GL (1987). Characterization of an N-methyl-D-aspartate receptor component of synaptic transmission in rat hippocampal slice. Neuroscience 22:1-8.
4. Creeley C, Wozniak DF, Labruyere J, Taylor GT, Olney JW (2006). Low doses of memantine disrupt memory in adult rats. J Neurosci 26:3923-3932.
5. Danysz W, Parsons CG (2003). The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease preclinical evidence. Int J Geriatr Psychiatry 18:S23-S32.
6. Danysz W, Gossel M, Zajaczkowski W, Dill D, Quack G (1994). Are NMDA antagonistic properties relevant for antiparkinsonian-like activity in rats? Case of amantadine and memantine. J Neural Transm Parkinsons 7:155-166.
7. Danysz W, Parsons CG, Bresink I, Quack G (1995). Glutamate in CNS disorders-A revived target for drug development. Drug News Perspect 8:261-277.
8. Danysz W, Parsons CG, Kornhuber J, Schmidt WJ, Quack G (1997). Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents: preclinical studies. Neurosci Biobehav Rev 21:455-468.
9. Davis SM, Lees KR, Albers GW, Diener HC, Markabi S, Karlsson G, Norris J (2000). Selfotel in acute ischemic stroke: possible neurotoxic effects of an NMDA antagonist. Stroke 31:347-354.
10. Enina G, Miglane E, Tilgale B (2002). Results from intrevenous administration of Akatinol Mematine for patients with stroke. Latvian Med J 3:25-29.
11. Gilling KE, Jatzke C, Parsons CG (2007). Agonist concentration-dependency of blocking kinetics but not equilibrium block of N-methyl-D- aspartate receptors by memantine. Neuropharmacology 53:415-420.
12. Greenamyre JT, Maragos EF, Albin RL, Penney JB, Young AB (1988). Glutamate transmission and toxicity in Alzheimer's disease. Prog Neuro-Psych Biol Psych 12:421-430.
13. Hesselink MB, DeBoer BG, Breimer DD, Danysz W (1999). Brain penetration and in vivo recovery of NMDA receptor antagonists amantadine and memantine: a quantitative microdialysis study. Pharmaceut Res 16:637-642.
14. Kieburtz K (2001). A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease. Neurology 57:397-404.
15. Kornhuber J, Quack G (1995). Cerebrospinal fluid and serum concentrations of the N-methyl-D-aspartate (NMDA) receptor antagonist memantine in man. Neurosci Lett 195:137-139.
16. Kornhuber J, Bormann J, Hubers M, Rusche K, Riederer P (1991). Effects of the 1-amino-adamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel: a human postmortem brain study. Eur J Pharmacol 206:297-300.
17. Kornhuber J, Kennepohl EM, Bleich S, Wiltfang J, Kraus T, Reulbach U, Meineke I (2007). Memantine pharmacotherapy: a naturalistic study using a population pharmacokinetic approach. Clin Pharmacokinet 46:599-612.
18. Lees KR, Lavelle JF, Cunha L, Diener HC, Sanders EA, Tack P, Wester P (2001). Glycine antagonist (GV150526) in acute stroke: a multicentre, double-blind placebo-controlled phase II trial. Cerebrovasc Dis 11:20-29.
19. Luhrs LB, Banerjee PK, LeFerla FM (2006). Memantine reverses cognitive deficits in transgenic mice with both plaques and tangles, 10th International Conference on Alzheimer and Associated Disorders, 15-20 July, Madrid, P1-001.
20. Meldrum B, Garthwaite J (1990). Excitatory amino acid neurotoxicity and neurodegenerative disease. Trends Pharmacol Sci 11:379-387.
21. Miguel-Hidalgo J, Paul I, Wanzo V, Hachicha M, Banerjee P (2005). Memantine inhibits the expression of caspase-8 and improves learning in rats injected with β-amyloid (Aβ1-40). 35th Society for Neuroscience Annual Meeting 31:12-16. November 2005, Washington, DC, USA, #1019.5.
22. Misztal M, Danysz W (1995). Comparison of glutamate antagonists in continuous multiple-trial and single-trial dark avoidance. Behav Pharmacol 6:550-561.
23. Misztal M, Frankiewicz T, Parsons CG, Danysz W (1996). Learning deficits induced by chronic intraventricular infusion of quinolinic acid-protection by MK-801 and memantine. Eur J Pharmacol 296:1-8.
24. More L, Gravius A, Greco S, Schmidt WJ, Nagel J, Danysz W (2007a). Neuroprotective doses of memantine do not impair learning. 37th Society for Neuroscience Annual Meeting 33, San Diego, USA, #936.12.
25. Morè L, Gravius A, Pietraszek M, Belozertseva I, Malyshkin A, Shekunova E, et al. (2007b). Comparison of the mGluR1 antagonist A-841720 in rat models of pain and cognition. Behav Pharmacol 18:273-281.
26. Morris GF, Bullock R, Marshall SB, Marmarou A, Maas A, Marshall LF (1999). Failure of the competitive N-methyl-D-aspartate antagonist Selfotel (CGS 19755) in the treatment of severe head injury: results of two Phase III clinical trials. J Neurosurg 91:737-743.
27. 3H]MK-801 binding to NMDA receptors in vivo and in vitro. Eur J Pharmacol 397:263-270.
28. Nagel J, Belozertseva I, Greco S, Kashkin V, Szydlowska K, Malyshkin A, et al. (2006). Effects of NAAG peptidase inhibitor 2-PMPA in model of chronic pain-relation to brain concentration. Neuropharmacology 51:1163-1171.
29. Nakamura S, Murayama N, Noshita T, Katsuragi R, Ohno T (2006). Cognitive dysfunction induced by sequential injection of amyloid-beta and ibotenate into the bilateral hippocampus; protection by memantine and MK-801. Eur J Pharmacol 548:115-122.
30. Novelli A, Reilly JA, Lysko PG, Henneberry RC (1988). Glutamate becomes neurotoxic via the N-methyl-D-aspartate receptor when intracellular energy levels are reduced. Brain Res 451:205-212.
31. Nowak L, Bregestovski P, Ascher P, Herbert A, Prochiantz A (1984). Magnesium gates glutamate-activated channels in mouse central neurons. Nature 307:462-465.
32. 1-42), The 10th International Conference on Alzheimers Disease and Related Disorders, 15-20 July, Madrid, P4-305.
33. Parsons CG, Gruner R, Rozental J, Millar J, Lodge D (1993). Patch clamp studies on the kinetics and selectivity of N-methyl-D-aspartate receptor antagonism by memantine (1-amino-3,5-dimethyladamantan). Neuropharmacology 32:1337-1350.
34. Parsons CG, Danysz W, Quack G (1999). Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist-a review of preclinical data. Neuropharmacology 38:735-767.
35. Parsons CG, Stoffler A, Danysz W (2007). Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system-too little activation is bad, too much is even worse. Neuropharmacology 53:699-723.
36. Paxinos G, Watson C (1986). The rats brain in stereotaxic coordinates. New York: Academic Press.
37. Periclou A, Ventura D, Rao N, Abramowitz W (2006). Pharmacokinetic study of memantine in healthy and renally impaired subjects. Clin Pharmacol Ther 79:134-143.
38. 3H]-MK-801. Eur J Pharmacol 158:279-282.
39. Ragozzino ME, Unick KE, Gold PE (1996). Hippocampal acetylcholine release during memory testing in rats: augmentation by glucose. Proc Natl Acad Sci U S A 93:4693-4698.
40. Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ (2003). Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 348:1333-1341.
41. Schmidt R, Ropele S, Ebenbauer B, Windisch M, Stoffler A, Fazekas F (2007). Memantine Effects on Brain Volume, Glucose Metabolism and Cognition in AD Patients: a Randomized Double-Blind, Placebo-Controlled Neuroimaging Study, 8th International conference AD/PD 2007, Alzheimer's and Parkinson's Diseases: Progress and New Perspectives, 4-18th March 2007, Salzburg, Austria, Abstract #819.
42. Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I (2004). Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 291:317-324.
43. Van Dam D, De Deyn PP (2006). Cognitive evaluation of disease-modifying efficacy of galantamine and memantine in the APP23 model. Eur Neuropsychopharmacol 16:59-69.
44. Van Dam D, Abramowski D, Staufenbiel M, De Deyn PP (2005). Symptomatic effect of donepezil, rivastigmine, galantamine and memantine on cognitive deficits in the APP23 model. Psychopharmacology (Berl) 180:177-190.
45. Wenk GL, Danysz W, Mobley SL (1995). MK-801, memantine and amantadine show neuroprotective activity in the nucleus basalis magnocellularis. Eur J Pharmac Env Tox Pharmacol 293:267-270.
46. Wenk GL, Danysz W, Roice DD (1996). The effects of mitochondrial failure upon cholinergic toxicity in the nucleus basalis. NeuroReport 7:1453-1456.
47. Wenk GL, Parsons CG, Danysz W (2006). Potential role of N-methyl-D-aspartate receptors as executors of neurodegeneration resulting from diverse insults: focus on memantine. Behav Pharmacol 17:411-424.
48. Willard LB, Hauss-Wegrzyniak B, Danysz W, Wenk GL (2000). The cytotoxicity of chronic neuroinflammation upon basal forebrain cholinergic neurons of rats can be attenuated by glutamatergic antagonism or cyclooxygenase-2 inhibition. Exp Brain Res 134:58-65.
49. Yamada K, Takayanagi M, Kamei H, Nagai T, Dohniwa M, Kobayashi K, et al. (2005). Effects of memantine and donepezil on amyloid beta-induced memory impairment in a delayed-matching to position task in rats. Behav Brain Res 162:191-199.
50. Zagulska-Szymczak S, Filipkowski RK, Kaczmarek L (2001). Kainate-induced genes in the hippocampus: lessons from expression patterns. Neurochem Int 38:485-501.
51. Zajaczkowski W, Quack G, Danysz W (1996). Infusion of (+)-MK-801 and memantine-contrasting effects on radial maze learning in rats with entorhinal cortex lesion. Eur J Pharmacol 296:239-246.
52. Zajaczkowski W, Hetman M, Nikolaev E, Quack G, Danysz W, Kaczmarek L (2000). Behavioural evaluation of long-term neurotoxic effects of NMDA receptor antagonists. Neurotox Res 1:299-310.
53. Zoladz PR, Campbell AM, Park CR, Schaefer D, Danysz W, Diamond DM (2006). Enhancement of long-term spatial memory in adult rats by the noncompetitive NMDA receptor antagonists, memantine and neramexane. Pharmacol Biochem Behav 85:298-306.